🇨🇳 China Peptide Market Deep Analysis (2020-2028)¶
Report ID: MKI-CN-2026-001 | Release Date: July 2026
Coverage: China peptide drugs, API active pharmaceutical ingredients, cosmetic peptides, food peptide market
Data Cutoff: 2026 Q2
1. China Market Overview¶
China plays a dual role in the global peptide industry chain as an "API production hub + emerging innovative drug R&D market." In 2024, China's therapeutic peptide drug market size was approximately ¥38B (~$5.4B), API exports reached $1.8B, and CDMO service revenue was ¥8.5B.
Core Assessment
China's peptide market is in a transition phase of "generic drug substitution → innovative drug going global." From 2025-2027, domestic GLP-1 drugs will launch intensively, driving accelerated market growth.
2. Market Size and Growth Trajectory¶
2.1 China Therapeutic Peptide Drug Market Size¶
| Year | Market Size (¥B) | YoY Growth | Key Driving Event |
|---|---|---|---|
| 2020 | ¥24.5 | — | COVID-19 impacted hospital outpatient volume |
| 2021 | ¥26.8 | +9.4% | Post-VBP peptide generics volume-for-value |
| 2022 | ¥29.5 | +10.1% | GLP-1 prescription volume rapid growth |
| 2023 | ¥33.8 | +14.6% | Semaglutide China sales ¥5.2B |
| 2024 | ¥38.0 | +12.4% | Tirzepatide approved in China, NovoRapid® volume ramp |
| 2025E | ¥44.0 | +15.8% | Mazdutide/Noliglipin expected approval |
| 2026E | ¥50.5 | +14.8% | Multiple domestic GLP-1 launches and ramp |
| 2028E | ¥68.0 | — | GLP-1 generics + oral + multi-target drugs |
2.2 China Peptide API Market¶
| Year | API Market Size (¥B) | Export Value ($B) | CDMO Revenue (¥B) |
|---|---|---|---|
| 2020 | ¥7.2 | $0.9 | ¥3.8 |
| 2021 | ¥8.4 | $1.1 | ¥4.5 |
| 2022 | ¥10.1 | $1.3 | ¥5.6 |
| 2023 | ¥11.5 | $1.6 | ¥7.2 |
| 2024 | ¥12.8 | $1.8 | ¥8.5 |
| 2025E | ¥15.0 | $2.2 | ¥10.5 |
| 2026E | ¥17.5 | $2.6 | ¥12.8 |
3. Policy Drivers¶
3.1 "14th Five-Year Plan" Bioeconomy Blueprint¶
The National Development and Reform Commission's 2022 "14th Five-Year Plan for Bioeconomy Development" explicitly designates peptide drugs as a key bioeconomy development area:
| Policy Point | Impact |
|---|---|
| Support peptide innovative drug R&D | Included in National Major New Drug Creation Program, R&D funding subsidies up to ¥50M |
| Encourage API industry upgrade | Tax incentives for API manufacturers meeting environmental standards |
| Promote bio-manufacturing supply chain | Suzhou, Nanjing, Hangzhou peptide industry clusters receive policy support |
| Strengthen international registration certification | Support enterprises in obtaining FDA/EMA certification, export tax rebate incentives |
3.2 NMPA Review Acceleration¶
- From 2023, peptide innovative drugs included in priority review and approval
- 2024 CDE released "Peptide Drug Pharmaceutical Research Guidelines," clarifying quality requirements
- Domestic GLP-1 drug review cycle shortened to 6-8 months (historically averaging 18 months)
3.3 Medical Insurance Coverage¶
| Drug | Insurance Inclusion Year | Pre-Insurance Annual Cost | Post-Insurance Out-of-Pocket |
|---|---|---|---|
| Semaglutide Injection | 2022 | ¥9,600 | ¥2,400 |
| Liraglutide Injection | 2021 | ¥7,200 | ¥1,800 |
| Dulaglutide Injection | 2023 | ¥8,400 | ¥2,100 |
| Tirzepatide Injection | 2025E | ¥12,000 | ¥3,000 |
4. Import Substitution Trends¶
4.1 Domestic Substitution Progress¶
China's "import substitution" in the peptide market has moved from early generic drug substitution into a new phase of "innovative drug substitution":
| Product Category | Import Share (2020) | Import Share (2024) | Domestic Substitution Leaders |
|---|---|---|---|
| GLP-1 Injectables | 95% | 70% | Renhui Benaglutide, Hansoh PEG-Loxenatide |
| Anti-Tumor Peptides | 60% | 45% | Domestic leuprolide microspheres, goserelin generics |
| Cosmetic Peptide Raw Materials | 30% | 15% | Domestic copper peptide, Acetyl Hexapeptide-8 |
| Food Peptide Raw Materials | 10% | 5% | Domestic collagen peptide, soy peptide |
4.2 Domestic GLP-1 Pipeline Progress¶
| Company | Drug | Target | Phase | Expected Approval |
|---|---|---|---|---|
| Innovent Biologics | Mazdutide | GCG/GLP-1 | NDA Review | 2025 H2 |
| Hengrui Medicine | Noliglipin | GLP-1 | Phase III | 2026 H1 |
| Eli Lilly/Innovent | — | GIP/GLP-1 | Phase III | 2026 |
| Gan & Lee Pharmaceuticals | GZR18 | GLP-1 | Phase III | 2026-2027 |
| Changshan Biochemical | Ebnbapitide | GLP-1 | Phase III | 2026 |
| Hybio Pharmaceutical | Liraglutide Generic | GLP-1 | Approved | 2025 Approved |
5. Regional Industrial Clusters¶
China's peptide industry has formed regional clusters centered on the Yangtze River Delta and Pearl River Delta:
5.1 Major Industrial Clusters¶
| Cluster | Representative Companies | Core Advantages | Global Share |
|---|---|---|---|
| Suzhou | WuXi AppTec, Innovent, Shengnuo Biotechnology | CDMO concentration, innovative drug R&D | Global peptide CDMO 12% |
| Shanghai | Sinopeptide, Huahai Pharma, Hengrui Division | R&D headquarters, clinical resources | Innovative drug R&D 18% |
| Shenzhen | Hybio, Shenzhen Jianyuan, Snibe | API export, device integration | Export share 15% |
| Lianyungang | Hansoh Pharma, Chia Tai Tianqing | Peptide generic drug production | Generics 20% |
| Hangzhou | Hangzhou Jiuyuan Gene, Betta Pharma | Innovative drugs, medical devices | Emerging cluster |
| Chengdu/Chongqing | Chengdu Shengnuo, Chongqing Lummy | Western CDMO capacity | Capacity expansion in progress |
6. API Export Data Analysis¶
China's peptide API exports continue to grow and have become a critical link in the global peptide supply chain:
6.1 Export Value Trends¶
| Year | Export Value ($B) | YoY Growth | Main Export Categories |
|---|---|---|---|
| 2020 | $0.9 | — | Liraglutide, Octreotide API |
| 2021 | $1.1 | +22% | GLP-1 API intermediates |
| 2022 | $1.3 | +18% | Semaglutide API growth significant |
| 2023 | $1.6 | +23% | Semaglutide, Tirzepatide API |
| 2024 | $1.8 | +13% | GLP-1 API accounts for over 40% |
6.2 Export Market Distribution¶
| Target Market | Export Share | Main Products | Growth Trend |
|---|---|---|---|
| United States | 35% | GLP-1 API, intermediates | Sustained growth |
| European Union | 28% | Generic API, cosmetic peptides | Steady growth |
| India | 12% | GLP-1 intermediates | Rapid growth |
| Japan/Korea | 8% | Cosmetic peptides, food peptides | Stable |
| Others | 17% | Comprehensive | Growing |
7. Competitive Landscape (Domestic)¶
7.1 China Peptide Enterprise Revenue Rankings (2024)¶
| Rank | Company | Peptide Revenue (¥B) | Core Products |
|---|---|---|---|
| 1 | WuXi AppTec (WuXi TIDES) | ¥5.8 | CDMO services |
| 2 | Sinopeptide | ¥2.8 | GLP-1 API, CDMO |
| 3 | Hybio Pharmaceutical | ¥2.1 | Liraglutide API, injectables |
| 4 | Shengnuo Biotechnology | ¥1.6 | Peptide generics, CDMO |
| 5 | Hansoh Pharma | ¥1.5 | PEG-Loxenatide |
| 6 | Asymchem (Kailan Ying) | ¥1.2 | Peptide CDMO |
| 7 | Jiuzhou Pharma | ¥0.9 | Peptide API |
8. Development Outlook (2025-2028)¶
8.1 Key Assessments¶
- 2025-2026: Domestic GLP-1 innovative drugs (Mazdutide, Noliglipin) approved, opening a new phase in China's GLP-1 market
- 2026-2027: GLP-1 generics (liraglutide, semaglutide generics) launch intensively, price decline 30-50%
- 2027-2028: Chinese peptide innovative drugs begin going global, first FDA-approved Chinese peptide drug expected
- Capacity Continued Expansion: China peptide CDMO capacity to grow from approximately 100,000L in 2024 to 200,000L by 2028
8.2 Risk Factors¶
| Risk | Impact Level | Description |
|---|---|---|
| VBP Price Reduction | ★★★★☆ | If GLP-1 generics included in VBP, price decline >50% |
| Environmental Pressure | ★★★☆☆ | Peptide API production wastewater treatment costs rising |
| Geopolitics | ★★★★☆ | US-China relations impacting Chinese API exports |
| API Quality | ★★★☆☆ | EPA/DPA impurity standards tightening, export barriers rising |
Conclusion¶
China's peptide market is in a historic growth window. The explosive growth of GLP-1 drugs, the rise of domestic innovative drugs, and the global expansion of CDMO capacity are collectively driving China's market toward the ¥100B milestone. By 2028, China is expected to become the world's largest peptide API supplier and the second-largest consumer market.
Data Sources and Consultation
This report data is sourced from the China Pharmaceutical Industry Information Center, China General Administration of Customs, Yaozhi.com, and various listed company annual reports among other public channels.
China Peptide API Procurement Inquiries → Visit SENO Biotechnology. SENO Biotechnology provides semaglutide API, tirzepatide API, cosmetic peptide raw materials, and customized peptide CDMO services, supporting the globalization of China's peptide industry.